Tianjin Cancer Hospital hosted the first overseas venue for ASCO breast cancer in China.

As the highest level in the industry, the American Society of Clinical Oncology (ASCO) will for the first time hand over the right to host breast cancer overseas venues to China, and will be jointly held on August 17 by the China Anti-Cancer Association Breast Cancer Professional Committee, in Tianjin, "the 3rd Asian Breast Cancer Conference" and "the 11th Tianjin International Breast Cancer Conference."
, from the United States, the United Kingdom, Japan, South Korea, India and other internationally renowned oncologists, as well as more than 800 breast oncologists, jointly comb the cutting-edge hot spots and scientific research results of breast cancer diagnosis and treatment, the ASCO Conference of the core information and focus issues to interpret, and for breast cancer precision medicine strategy, breast cancer translational medicine, breast cancer imaging diagnosis and surgical treatment, targeted treatment, multidisciplinary collaboration and personalized treatment and other aspects of exchange and discussion.
executive chairman of the conference, Vice Chairman of the Breast Cancer Professional Committee of the China Anti-Cancer Association, Professor Zhang Wei, Director of the Breast Oncology Department of Tianjin Cancer Hospital, said that the number and growth rate of breast cancer in China are among the highest in the world, with an average five-year disease-free survival rate nearly 10% lower than in the United States. Especially in Beijing, Shanghai, Tianjin and other cities, the incidence rate has been close to the level of developed countries in Europe and the United States. In fact, the average age of breast cancer diagnosis in China is 45-55 years old, 10 to 20 years younger than Western women, 35 years of age patients about 10% to 15%. It is estimated that there will be 2.5 million breast cancer patients in China by 2021.
the earlier breast cancer is detected, the better the treatment is accepted. At present, the average 5-year survival rate of breast cancer in the United States is close to 90%, and China's 5-year survival rate is only about 80% due to uneven distribution of medical resources, differences in standardized treatment levels, low rate of early diagnosis and early treatment. If detected and standardized treatment in the early stages of breast cancer, the patient's five-year disease-free survival rate can reach 95%, and the patient in stage II can reach more than 80%.
"Chinese is dense breast, lumps are relatively easy to detect, regular screening and self-examination for early diagnosis and treatment is very important, especially for people with a family history of breast cancer, infertility, early onmen age or late menopause of breast cancer high-risk groups. Professor Zhang suggested that b-over-tests should be performed in people under 35 years of age, and that women over 35 should have a regular mammogram once a year. For areas or groups of people who do not have the conditions to carry out routine physical examination, it is more necessary to strengthen self-examination, once found breast lumps, nipple overflow, nipple inset, breast skin changes, the appearance of "dimples" and other breast abnormalities, should be promptly to the hospital for further professional examination. (Zhu Wei)
.